Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia
Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia
复制标题
DOI：
10.1016/j.humimm.2010.02.010
复制
发表时间：
2010-06-01
期刊：
影响因子：
2.7
通讯作者：
Yang, Renchi
中科院分区：
文献类型：
--
作者：
Gu, Dongsheng;Chen, Zhenping;Yang, Renchi
免疫性血小板减少症（ITP）是一种获得性器官特异性自身免疫性疾病，具有T（h）1极化。T（h）1趋化因子CXCL 10和T（h）2趋化因子CCL 2已在几种自身免疫性疾病中进行了研究，但这些趋化因子在ITP中的地位仍然未知。本研究的目的是确定CXCL 10和CCL 2及其受体的表达。CXCR 3和CCR 2在ITP患者中的表达，并初步探讨这些因子在ITP发病中的作用。采用酶联免疫吸附法测定49例ITP患者和24例正常人血浆中CXCL 10和CCL 2的浓度。应用实时荧光定量聚合酶链反应（RT-PCR）检测24例正常对照、28例活动期ITP患者外周血单个核细胞（PBMNC）及9例ITP患者脾细胞中趋化因子及其受体的mRNA表达。活动期ITP患者血浆中CXCL 10水平显著高于健康对照组（p = 0.007），缓解期ITP患者血浆中CXCL 10水平降至正常水平。相比之下，CCL 2水平在活动性疾病患者、缓解患者和对照受试者中相似。活动性疾病患者PBMNC表达更多CXCL 10 mRNA（p = 0.031），但较少CCR 2 mRNA（p = 0.005）。较低的外周血小板计数与较高的CXCL 10水平和CXCL 10/CCL 2比值相关。我们的研究表明，活动性ITP患者血浆CXCL 10水平和CXC 10/CCL 2比值高于健康献血员，并与患者的血小板计数相关。CXCL 10可能是本病的致病因子。(C)2010年美国组织相容性和免疫遗传学学会。爱思唯尔公司出版All rights reserved.
Immune thrombocytopenia (ITP) is an acquired organ-specific autoimmune disease with a polarization of T(h)1. Both the T(h)1 chemokine CXCL10 and T(h)2 chemokine CCL2 have been studied in several autoimmune diseases, but the status of these chemokines in ITP is still unknown. The aims of this study were to determine the expression of CXCL10 and CCL2 and their receptors. CXCR3 and CCR2, in ITP patients, and to conduct a preliminary study of the pathogenic roles of these factors in ITP. Plasma samples from 49 patients with ITP and 24 normal healthy subjects were assayed for CXCL10 and CCL2 plasma concentration by enzyme-linked immunosorbent assay. Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of these chemokines and their receptors in the PBMNC of 24 normal controls and 28 active ITP patients as well as splenocytes of nine ITP patients. The CXCL10 levels in the plasma samples from patients with active ITP were significantly higher than those from healthy controls (p = 0.007) and decreased to normal levels in patients with remission ITP. In contrast, CCL2 levels were similar in patients with active disease, patients in remission, and control subjects. PBMNC of patients with active disease expressed more CXCL10 mRNA (p = 0.031) but less CCR2 mRNA (p = 0.005). Lower peripheral platelet count correlated with higher CXCL10 levels and CXCL10/CCL2 ratios. Our study demonstrated that plasma levels of CXCL10 and CXC10/CCL2 ratio were higher in patients with active ITP than in healthy donors, and had an association with platelet counts of the patients. CXCL10 might be a pathogenic factor of this disorder. (C) 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.